NOVARTIS

  • Google to develop 'smart' contact lenses July 15, 2014

    Zurich: Swiss drugmaker Novartis has struck an agreement with Google to develop "smart" contact lenses that would help diabetics track their blood glucose levels or restore the eye's ability to focus. The device for diabetics would measure glucose in tear fluid and send the data wirelessly to a mobile device, Novartis...
  • US business groups urge Biden to ask India to change policies July 23, 2013

    New Delhi: The US business groups on Monday urged Vice President Joe Biden to press India's leaders this week to reverse course on a number of government policies they said unfairly harm US companies that do business in the world's largest democracy. "Unfortunately, many US companies are facing serious issues doing...
  • US: NY lawsuit accuses Novartis of healthcare fraud April 24, 2013

    New York: The US government has sued Novartis Pharmaceuticals Corp, claiming it gave kickbacks to pharmacies to switch kidney transplant patients from competitors' drugs to its own. The civil health care fraud lawsuit in US District Court in Manhattan seeks unspecified damages and civil penalties for a scheme that the...
  • Novartis verdict will encourage genuine innovation: Prathiba M Singh April 3, 2013

    Prathiba M Singh, advocate for Ranbaxy and Cipla, fought the Glivec patent case against Novartis. She joined IBNLive readers for an interaction on the legal and moral compulsions behind this courtroom battle and the significance of the Supreme Court's decision for Indian pharma firms and the people of the country. Q....
  • 'US industry reviewing SC decision on Novartis' April 3, 2013

    Washington: The US industry on Wednesday said it is reviewing the order of the Supreme Court early this week that denied patent on Glivec, a cancer medication produced by Swiss drug maker Novartis, as Corporate America expressed dismay at the court verdict. "We are aware of the Supreme Court decision and...
  • 'SC order on Novartis will impact investment in India' April 3, 2013

    Washington: Expressing unease over the Supreme Court ruling against pharmaceutical giant Novartis denying the company a patent on its cancer drug, a major business advocacy group on Tuesday said that this would impact innovation and investment climate in India at a time when the country needs foreign direct investment the...
  • FTN: SC ruling on Novartis: Should cancer drugs be cheaply available? April 2, 2013

    In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving drug. ...
  • Novartis cannot ignore India's huge market: Indian Pharmaceutical Alliance April 1, 2013

    The secretary general of the Indian Pharmaceutical Alliance, DG Shah said that Novartis was merely posturing and it could not ignore the huge market that India provided to its products. ...
  • Patent case: Decision on legal recourse after reading SC judgement, says Novartis April 1, 2013

    The Supreme Court on Monday dismissed Swiss drugmaker Novartis's attempt to win patent protection for its cancer drug Glivec. ...
  • Investments in India by global pharma cos to continue: Vikas Dandekar April 1, 2013

    In a landmark verdict, the Supreme Court dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving the way for more affordable lifesaving cancer drugs. How does it affect the Indian pharmaceutical industry and the global biggies who are looking...
  • 'Has to be a balance between innovation, affordability of drugs' April 1, 2013

    After the Supreme Court dismissed Swiss pharma company Novartis' plea for a patent on its cancer drug Glivec, pharma expert vikas Dandekar said, "This will be a far reaching decision. Innovation on one side, access and affordability on the other side. The balance has to be done". ...
  • Will now invest in India 'cautiously', says Novartis April 1, 2013

    Mumbai: Pharmaceutical giant Novartis on Monday termed the Supreme Court's judgement of not granting a patent to its cancer drug Glivec as "disappointing" and warned that though it will continue to introduce new products in India, it will now invest "cautiously". In a landmark verdict, the apex court dismissed the...
  • Cancer Patients Aid Association hails SC's verdict April 1, 2013

    In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving cancer drugs. "Generic companies will have a levy that will allow them to survive in...
  • 'SC ruling discourages innovative drug discovery' April 1, 2013

    New Delhi: Swiss pharmaceutical company Novartis, which lost its battle for patent on its cancer drug Glivec in India on Monday, said the Supreme Court's ruling discourages innovative drug discovery and is a setback for patients. "Novartis has never been granted an original patent for Glivec in India. We strongly believe...
  • Generic cancer drug to cost 92 pc less than Novartis's Glivec April 1, 2013

    New Delhi: The Supreme Court's denial of a patent to Novartis for its cancer drug Glivec in India is a blow to the pharmaceutical company, but a big relief for the patients. The generic cancer drug costs around Rs 10,000 for a monthly dosage, which is a fall of almost...
  • Novartis stock down 4.5 per cent after SC verdict April 1, 2013

    Mumbai: Shares of the Swiss pharmaceutical giant Novartis fell about 4.5 per cent on Monday after the Supreme Court of India dismissed its plea for a patent on its cancer drug, Gelvic. Shares of select Indian pharmaceutical companies rallied as the industry is set to receive a boost following the...
  • Timeline: Novartis's patent plea for Glivec in India April 1, 2013

    New Delhi: The Supreme Court dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving cancer drugs. Novartis had sought to overturn a clause in Indian Patents Law that restricts patent protection for newer...
  • SC denies patent to Novartis for Glivec April 1, 2013

    New Delhi: In a landmark verdict, the Supreme Court of India dismissed a plea by the Swiss pharmaceutical giant Novartis on Monday for a patent on its cancer drug Glivec, paving way for more affordable life saving cancer drugs. Novartis had sought to overturn a clause in Indian Patents Law...
  • SC verdict on Novartis's cancer drug Glivec today April 1, 2013

    New Delhi: The Supreme Court on Monday is likely to pronounce its verdict in the much awaited patent case involving Glivec the anticancer drug manufactured by Swiss pharmagiant Novartis priced at a whopping Rs 1.2 lakhs for a monthly dosage. The case dates back to India's denial of...
  • SC again asks Novartis to cut cancer drug price September 13, 2012

    New Delhi: The Supreme Court on Wednesday once again asked pharma company Novartis to scale down the price of its cancer drug Glivec, made from compound imatinib mesylate. The court suggested the price cut saying that the company's scheme for providing the drug free to poor patients was complicated. The court said...
  • Focus: Know your diabetes November 16, 2009

    Experts answer queries and advise on tackling diabetes. ...
  • Human trial of swine flu vaccine to begin in India September 2, 2009

    New Delhi: Search for a H1N1 Influenza A (swine flu) has intensified in India even as at least 100 people have already succumbed to the virus across the country. With the death toll due to swine flu rising, the Health Ministry has decided to give a go ahead to clinical trials...
  • Instant remedy: Pharma co ready with swine flu vaccine June 13, 2009

    New Delhi: The world is now at the start of the 2009 influenza pandemic says the WHO. The good news a pharmaceutical company says it's ready with a vaccine. Swiss pharmaceutical company Novartis says it has successfully produced a first batch of swine flu vaccine, weeks ahead of...
  • HC snubs Novartis petition, cancer patients relieved August 7, 2007

    Mumbai: Thirty twoyearold Laxman Bhaskar has been using a screen printer to earn a living for the last eight years working for the Cancer Patients Aid Association. The Association has generously supported him with a salary of Rs 3,000 apart from footing a hefty medicine bill that Laxman spends on...
  • Novartis loses patent battle for cancer drug August 7, 2007

    Chennai: It's a milestone for Indian patent laws and promises some relief for cancer patients. After months of delay, the Madras High Court on Monday dismissed drug company Novartis' move to patent its generic drug Glivec. The Court held as valid a legal provision unique to India, which states...
  • New wonder drug could treat blindness October 7, 2006

    London: Swiss drug maker Novartis has developed a drug that could treat blindness by combating the wet form of a condition called agerelated macular degeneration (AMD). AMD usually affects people above 60 years of age and the wet form progresses quickly and can cause blindness. The drug called Lucentis was tried on...
  • Hearing on cancer drug dispute begins September 26, 2006

    New Delhi: Hearing on the case in which Swiss pharmaceutical giant Novartis seeks a patent for its popular cancer drug Gleevec began on Tuesday. The trial is seen as a test for country's new patent law, which has been criticised by public health activists for favouring multinational companies. Earlier this year, Novartis...